Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes

J Atheroscler Thromb. 2002;9(6):280-7. doi: 10.5551/jat.9.280.


In a study population, we compared the level of malondialdehyde-modified LDL (MDA-LDL) with the concentrations of lipid parameters in serum and found a strong correlation between MDA-LDL and apolipoprotein B (apo B) concentrations. Their interrelations had a turning point at an apo B concentration of 1,150 mg/l. In diabetic patients, the ratio of MDA-LDL/apo B increased at apo B concentrations above 1,150 mg/l. This ratio represents the extent of modification of apo B by MDA. In the control subjects, this ratio remained stable. When we divided the patients into medication groups (statins and insulin), we found that the 1,150 mg/l threshold disappeared. At apo B concentrations above 1,150 mg/l, the ratio of MDA-LDL/apo B in the statin group was as high as that in the non-drug group. In the insulin group, the means of MDA-LDL/apo B in all ranges of apo B levels decreased to an extent statistically indistinguishable from those of the control group. In conclusion, insulin therapy represses LDL oxidation even at apo B concentrations > 1,150 mg/l and should be noted for its anti-oxidation properties.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apolipoproteins B / metabolism
  • Cholesterol, HDL / metabolism
  • Cholesterol, LDL / metabolism*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Electrophoresis
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Hypolipidemic Agents / administration & dosage
  • Insulin / administration & dosage*
  • Lipoproteins, LDL / metabolism
  • Male
  • Malondialdehyde / metabolism
  • Middle Aged
  • Triglycerides / metabolism
  • fas Receptor / metabolism


  • Apolipoproteins B
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Insulin
  • Lipoproteins, LDL
  • Triglycerides
  • fas Receptor
  • oxidized low density lipoprotein
  • Malondialdehyde